Compare VELO & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VELO | ASMB |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | 134 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.9M | 512.1M |
| IPO Year | N/A | 2010 |
| Metric | VELO | ASMB |
|---|---|---|
| Price | $11.48 | $24.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $18.00 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 1.7M | 138.4K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.22 | N/A |
| Revenue Next Year | $50.08 | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.87 | $18.41 |
| 52 Week High | $31.75 | $39.71 |
| Indicator | VELO | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 44.76 |
| Support Level | $8.33 | $21.80 |
| Resistance Level | $11.92 | $30.36 |
| Average True Range (ATR) | 1.19 | 1.32 |
| MACD | 0.29 | -0.15 |
| Stochastic Oscillator | 61.15 | 17.26 |
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.